Labcorp Holdings Inc.

• LH Stock Price 24h change: +1.69%. From 250.39 USD to 254.63 USD.
• From a technical perspective, LH presents a "bearish consolidation with potential oversold rebound": indicators show a Strong Sell trend with major moving averages (MA5, MA20, MA200) all trending downward. However, an RSI near 36 and a STOCHRSI near 0 suggest the stock is reaching oversold territory, making it prone to short-term technical bounces following the dividend announcement.
• Labcorp Board of Directors declared a quarterly cash dividend of $0.72 per share on January 14, 2026, payable on March 12 to stockholders of record as of February 27.
• Labcorp expanded its molecular residual disease (MRD) portfolio earlier this week, making Plasma Detect Genome testing for colon cancer available nationwide and adding new assays for breast and lung cancer.
• Large institutional shifts were reported on January 13, with Nordea Investment Management decreasing its holdings by 16.8% while Mitsubishi UFJ and Lazard Asset Management increased their stakes.
• Healthcare CFOs entering 2026 report heightened external pressures, citing rising utilization levels and regulatory volatility as key financial risks that could impact medical loss ratios (MLRs).
• The healthcare sector is emerging as a market leader in early 2026, with the XLV ETF reaching fresh highs as investors rotate from technology into healthcare for a mix of innovation and attractive forward P/E valuations.

• LH Stock Price 24h change: -0.56%. From 251.81 USD to 250.39 USD. (As of January 12, 2026 close).
• From a technical perspective, LH presents a "bearish consolidation" phase. The stock is currently trading below its 50-day ($258.95) and 200-day ($265.90) moving averages, indicating downward pressure. However, a neutral RSI (near 36.5) and a buy signal from the MACD (-3.13) suggest the stock may be bottoming out near the 245-250 USD support zone, awaiting a catalyst for a reversal.
• Labcorp's executive leadership is participating in the 44th Annual J.P. Morgan Healthcare Conference (Jan 12-15, 2026), where they are expected to discuss 2026 guidance and growth strategies in diagnostic and biopharma services.
• NAMSA announced the strategic acquisition of select assets from Labcorp’s Early Development Medical Device Testing business on January 8, allowing Labcorp to further streamline its core clinical laboratory and drug development focus.
• Visby Medical engaged Labcorp and Quest Diagnostics on January 8 to expand consumer access to the first FDA-authorized at-home PCR test for STIs, strengthening Labcorp's position in the growing decentralized testing market.
• The 44th Annual J.P. Morgan Healthcare Conference kicked off on January 12 in San Francisco, featuring major presentations from industry giants like Eli Lilly and Pfizer, focusing on AI integration in drug discovery and M&A activity.
• NVIDIA doubled down on life-sciences AI on January 12, announcing a co-innovation lab with Eli Lilly and new partnerships with diagnostics firms like Natera to accelerate precision medicine through GPU-accelerated models.